The ERLIN2-knockdown breast cancer cells were exquisitely more sensitive to low doses of Bortezomib treatment, with an IC50 value as low as 0.467 ng ml−1, compared with the control breast cancer cells with an IC50 of 8.027 (Figure 7e). This evidence concerns the gene ERLIN2 and breast carcinoma.